News headlines about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.8791590353859 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Keryx Biopharmaceuticals, Inc. (KERX) stock price ends at $4.09 with performance of 1.49% on volume of 909776 shares (nasdaqexpress.com)
- Quick notice on Oversold Stock: Keryx Biopharmaceuticals, Inc. (KERX) stock Upward Move Ahead (nasdaqchronicle.com)
- Stifel Nicolaus Lowers Keryx Biopharmaceuticals (KERX) Price Target to $5.00 (americanbankingnews.com)
- Keryx Biopharmaceuticals Inc (NASDAQ:KERX) Institutional Investors 2017 Q4 Sentiment (malibureport.com)
- Active Stock Evaluation – Keryx Biopharmaceuticals Inc (NASDAQ: KERX) (stockspen.com)
KERX traded down $0.09 on Monday, reaching $4.00. 489,271 shares of the company traded hands, compared to its average volume of 1,277,324. Keryx Biopharmaceuticals has a 52-week low of $3.94 and a 52-week high of $8.38. The company has a market capitalization of $487.43, a PE ratio of -4.59 and a beta of 2.60. The company has a debt-to-equity ratio of -8.87, a quick ratio of 2.49 and a current ratio of 3.12.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.08). Keryx Biopharmaceuticals had a negative net margin of 269.52% and a negative return on equity of 10,954.62%. The company had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $17.53 million. During the same period in the previous year, the firm posted ($0.32) earnings per share. The business’s revenue for the quarter was up 96.8% on a year-over-year basis. equities analysts forecast that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.
KERX has been the topic of a number of recent analyst reports. BidaskClub lowered shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 20th. ValuEngine lowered shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, February 22nd. Finally, Morgan Stanley cut their price target on shares of Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, February 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $7.19.
In related news, COO Christine A. Carberry sold 9,048 shares of the business’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $4.87, for a total transaction of $44,063.76. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Scott A. Holmes sold 5,651 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total transaction of $27,181.31. The disclosure for this sale can be found here. Insiders have sold 43,182 shares of company stock worth $208,175 over the last ninety days. 2.58% of the stock is currently owned by insiders.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.